undamentalytics Newsletter
Sign in

Bioage Labs, Inc. income statement

In fiscal 2025, Bioage Labs, Inc. reported revenue of $9.0m, operating income of −$92.8m (a -1031.5% margin) and net income of −$80.6m, or −$2.24 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Revenue0910
Research and development597488
General and administrative192829
Operating income−78−93−106
Interest expense210
Income before tax−71−81—
Income tax00—
Net income−71−81−94
Diluted EPS−$6.63−$2.24−$2.37
Diluted shares (average)11m36m40m
EBITDA−78−93—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BIOA vs RLAYBIOA vs CRBUBIOA vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Bioage Labs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bioage Labs, Inc.